Cargando…
Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications
Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorpt...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474/ https://www.ncbi.nlm.nih.gov/pubmed/33914397 http://dx.doi.org/10.1111/1744-9987.13663 |
_version_ | 1784749142990389248 |
---|---|
author | Fuchs, Kornelius Rummler, Silke Ries, Wolfgang Helmschrott, Matthias Selbach, Jochen Ernst, Friedlinde Morath, Christian Gauly, Adelheid Atiye, Saynab Stauss‐Grabo, Manuela Giefer, Mareike |
author_facet | Fuchs, Kornelius Rummler, Silke Ries, Wolfgang Helmschrott, Matthias Selbach, Jochen Ernst, Friedlinde Morath, Christian Gauly, Adelheid Atiye, Saynab Stauss‐Grabo, Manuela Giefer, Mareike |
author_sort | Fuchs, Kornelius |
collection | PubMed |
description | Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorption were the aim of this study. This prospective, noninterventional, multicentre cohort study included patients treated with immunoadsorption (Immunosorba or GLOBAFFIN adsorbers) for any indication. Clinical effectiveness was assessed after termination of the patient's individual treatment schedule. Eighty‐one patients were included, 69 were treated with Immunosorba, 11 with GLOBAFFIN, one patient with both adsorbers. A majority of patients was treated for neurological indications, dilated cardiomyopathy, and before or after kidney or heart transplantation. Mean IgG reduction from pre‐ to post‐treatment was 69.9% ± 11.5% for Immunosorba and 74.1% ± 5.0% for GLOBAFFIN, respectively. The overall IgG reduction over a complete treatment block was 68%–93% with Immunosorba and 62%–90% with GLOBAFFIN depending on the duration of the overall treatment. After termination of the immunoadsorption therapy, an improvement of clinical status was observed in 63.0%, stabilization of symptoms in 29.6%, and a deterioration in 4.9% of patients. Changes in fibrinogen, thrombocytes, and albumin were mostly classified as noncritical. Overall, the treatments were well tolerated. Immunoadsorption in routine clinical practice with both GLOBAFFIN and Immunosorba has been safely performed, was well tolerated by patients, and effective in lowering immunoglobulins with an improvement or maintenance of clinical status, thus represents an additional therapeutic option for therapy refractory immune disorders. |
format | Online Article Text |
id | pubmed-9291474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-92914742022-07-20 Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications Fuchs, Kornelius Rummler, Silke Ries, Wolfgang Helmschrott, Matthias Selbach, Jochen Ernst, Friedlinde Morath, Christian Gauly, Adelheid Atiye, Saynab Stauss‐Grabo, Manuela Giefer, Mareike Ther Apher Dial Original Articles Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorption were the aim of this study. This prospective, noninterventional, multicentre cohort study included patients treated with immunoadsorption (Immunosorba or GLOBAFFIN adsorbers) for any indication. Clinical effectiveness was assessed after termination of the patient's individual treatment schedule. Eighty‐one patients were included, 69 were treated with Immunosorba, 11 with GLOBAFFIN, one patient with both adsorbers. A majority of patients was treated for neurological indications, dilated cardiomyopathy, and before or after kidney or heart transplantation. Mean IgG reduction from pre‐ to post‐treatment was 69.9% ± 11.5% for Immunosorba and 74.1% ± 5.0% for GLOBAFFIN, respectively. The overall IgG reduction over a complete treatment block was 68%–93% with Immunosorba and 62%–90% with GLOBAFFIN depending on the duration of the overall treatment. After termination of the immunoadsorption therapy, an improvement of clinical status was observed in 63.0%, stabilization of symptoms in 29.6%, and a deterioration in 4.9% of patients. Changes in fibrinogen, thrombocytes, and albumin were mostly classified as noncritical. Overall, the treatments were well tolerated. Immunoadsorption in routine clinical practice with both GLOBAFFIN and Immunosorba has been safely performed, was well tolerated by patients, and effective in lowering immunoglobulins with an improvement or maintenance of clinical status, thus represents an additional therapeutic option for therapy refractory immune disorders. John Wiley & Sons Australia, Ltd 2021-05-06 2022-02 /pmc/articles/PMC9291474/ /pubmed/33914397 http://dx.doi.org/10.1111/1744-9987.13663 Text en © 2021 Fresenius Medical Care Deutschland GmbH. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Fuchs, Kornelius Rummler, Silke Ries, Wolfgang Helmschrott, Matthias Selbach, Jochen Ernst, Friedlinde Morath, Christian Gauly, Adelheid Atiye, Saynab Stauss‐Grabo, Manuela Giefer, Mareike Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title | Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title_full | Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title_fullStr | Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title_full_unstemmed | Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title_short | Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
title_sort | performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291474/ https://www.ncbi.nlm.nih.gov/pubmed/33914397 http://dx.doi.org/10.1111/1744-9987.13663 |
work_keys_str_mv | AT fuchskornelius performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT rummlersilke performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT rieswolfgang performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT helmschrottmatthias performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT selbachjochen performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT ernstfriedlinde performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT morathchristian performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT gaulyadelheid performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT atiyesaynab performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT staussgrabomanuela performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications AT giefermareike performanceclinicaleffectivenessandsafetyofimmunoadsorptioninawiderangeofindications |